Syma Iqbal, MD

Professor of Clinical Medicine

Medical Director, Inpatient Services, Norris Cancer Hospital

Medical Director for Ambulatory Services/Infusion Center

Associate Cancer Physician in Chief

Image of Syma Iqbal, MD
Is this your profile? Click to edit

Overview

Dr. Syma Iqbal graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. She is currently an Associate Professor in the Division of Oncology at the Keck School of Medicine/Norris Comprehensive Cancer Center and Section Chief of Gastrointestinal Oncology. She is the Associate Cancer Physician in Chief for USC Norris Comprehensive Cancer Center and Keck Medicine of USC and serves as Medical Director of both Ambulatory/Infusion and Inpatient Services for Norris Cancer Hospital. Currently, Dr. Iqbal Chairs the Norris Clinical Investigations Committee. Dr. Iqbal is also an accomplished clinical researcher and has led and participated in trials for gastrointestinal malignancies. She is a national thought leader in the systemic therapy of esophageal and gastric cancer, and her national leadership posts include serving as co-Chair of the Southwest Oncology Group Esophago-Gastric Committee and Chair of the National Cancer Institute’s Esophago-Gastric Task Force.

Publications

  • NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. J Clin Oncol. 2026 Feb 20; 44(6):497-507.. View in PubMed
  • Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025 Jul; 26(7):847-859.. View in PubMed
  • Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial. Nat Commun. 2025 May 08; 16(1):4293.. View in PubMed
  • S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncol. 2025 May; 21(11):1325-1331.. View in PubMed
  • DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. J Clin Oncol. 2025 01 20; 43(3):339-349.. View in PubMed
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer. 2024 05 15; 154(10):1794-1801.. View in PubMed
  • Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023; 15:265-275.. View in PubMed
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022 05; 7(5):446-454.. View in PubMed
  • Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res. 2020 11 15; 26(22):5943-5951.. View in PubMed
  • Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist. 2020 12; 25(12):e1879-e1885.. View in PubMed